JAFRAL Partners with SCTbio and Oslo University Hospital on Next-Generation CAR-T Therapy
JAFRAL is proud to announce our involvement in a significant collaboration between SCTbio and Oslo University Hospital, focused on developing a next-generation CAR-T cell therapy targeting STEAP1, a tumor-associated antigen highly expressed in prostate cancer and Ewing sarcoma.
Our Role: Trusted Partner in High-Quality Plasmid Supply
As a CDMO specialized in biologics, JAFRAL contributes to this partnership by supplying both research-use-only and GMP-grade plasmids, strengthening the upstream supply chain for SCTbio’s vector production. This collaboration reflects our ongoing mission to support innovative therapies with high-quality, reliable manufacturing solutions.
Why This Partnership Matters
This project aligns directly with JAFRAL’s expertise and vision in cell and gene therapy, particularly CAR-T therapies for solid tumors, which remain one of the most challenging areas in oncology. By collaborating with SCTbio, we are helping to accelerate the development and delivery of next-generation therapies to patients globally.
For JAFRAL, this partnership is more than a collaboration—it’s a step toward our larger goal of turning new scientific ideas into real treatments. We are excited about the opportunities ahead and remain committed to supporting the advancement of cell and gene therapies worldwide.
